The Filing Desk

Janux Therapeutics

JANX · Nasdaq · Health Care · Financials, fiscal 2020 to 2025

JANX · Last close · November 13, 2026
$11.37
Value Janux Therapeutics yourself

Janux Therapeutics' revenue fell 5.5% to $10 million in fiscal 2025. Its operating margin was −1,576.7%, down from −933.6% a year earlier. Free cash flow was −$83 million. The diluted share count rose 15.3%.

Janux Therapeutics, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001193125-26-076918 Updated
Revenue
$10M
5.5%
Operating margin
−1,576.7%
643.1 pts
Net income
−$114M
 
Free cash flow
−$83M
 
Return on equity
−11.5%
1.4 pts
Market cap
$717M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Janux Therapeutics does

Janux Therapeutics is a clinical-stage drug company, which means it tests experimental medicines in people and has none approved for sale. It works on cancer immunotherapies, drugs that guide the body's immune system to attack tumors. Its main approach uses T cell engagers, which link a patient's immune cells to a cancer cell. Janux designs its versions to switch on mainly at the tumor, aiming to limit harm to healthy tissue.

Its first clinical candidate, JANX007, targets a protein called PSMA and is in a Phase 1 trial in men with metastatic castration-resistant prostate cancer. In 2025 it began expansion studies of the drug in specific groups of patients. The second, JANX008, targets a protein called EGFR and is in a Phase 1 trial in several solid tumor types. It also has a third platform, called ARM, aimed at autoimmune diseases as well as cancer. A Phase 1 study of its first ARM drug, JANX011, which targets B cells, has started in healthy volunteers. Its other programs are still in the discovery or preclinical stage.

Janux has no approved products and no revenue from selling drugs. It has lost money since it started and says it may never become profitable. It relies on outside organizations to run its clinical trials.

Its biggest risks, as it describes them

  • Net losses since it started, with no assurance it will ever earn revenue or profit.
  • Needing more capital, which could mean delaying programs or diluting shareholders.
  • Early-stage candidates: only JANX007 and JANX008 are in trials, and early results may not hold up later.
  • Novel technology that makes timing, results, cost and regulatory approval hard to predict.
  • Relying on outside organizations to run clinical trials, and on key personnel.
From Janux Therapeutics's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Janux Therapeutics lost money in fiscal 2025: a net loss of $114 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments3753273441,025967
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio29.5x20.1x26.8x59.2x39.0x
Quick ratio29.5x20.1x26.8x59.2x39.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Janux Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Janux Therapeutics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−654.7%−386.2%−838.3%
Altman Z''13.0932.6526.48
Accruals ratio−2.1%−3.5%−3.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassPassFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailPassFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Janux Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Janux TherapeuticsFY25−5.5%−1,576.7%−832.8%———
Taysha Gene TherapiesFY2517.3%−1,130.7%−960.1%——4Compare
Roivant SciencesFY25−71.6%−6,235.7%−9,183.5%−62.6%—1Compare
Arbutus BiopharmaFY25128.2%−271.0%−281.4%——3Compare
Relay TherapeuticsFY2553.4%−1,971.6%−1,536.1%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue04981110
Revenue growth——136.8%−6.1%31.0%−5.5%
Gross profit——————
Research and development326535568126
Operating income−5−33−67−73−99−158
Net income−7−33−63−58−69−114
Diluted EPS (US$)−7.41−1.39−1.52−1.32−1.28−1.83
Diluted shares (millions)12442445462
Cash flow
Cash from operations−4−17−43−51−44−82
Capital expenditure026201
Free cash flow−4−18−49−52−44−83
Dividends paid000000
Share buybacks000000
Acquisitions000000
Stock-based compensation0717203340
Balance sheet at fiscal year end
Cash and short-term investments83753273441,025967
Debt incl. finance leases——————
Total assets163803643801,0621,002
Total liabilities91443363945
Shareholders' equity−153663213441,023957
Margins and ratios
Gross margin——————
Operating margin—−905.4%−779.0%−902.9%−933.6%−1,576.7%
Net margin—−898.3%−732.2%−721.2%−651.6%−1,136.2%
Free cash flow margin—−507.5%−573.2%−648.6%−417.2%−832.8%
Rule of 40 (growth + FCF margin)——−436.4%−654.7%−386.2%−838.3%
Return on capital——————
Return on equity—−18.6%−18.4%−17.5%−10.1%−11.5%
Return on assets—−16.5%−17.0%−15.7%−9.6%−11.0%
Net debt to EBITDA——————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Janux Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Janux Therapeutics.